ArticleFrontiers in oncology2021
The Role of Preoperative Computed Tomography Radiomics in Distinguishing Benign and Malignant Tumors of the Parotid Gland.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- The study of nomogram model based on CT radiomics and clinical features for histological classification of parotid gland tumors.Scientific reports · 2026Article
- Deep-learning-based radiomics of intratumoral and peritumoral CT images to differentiate benign from malignant parotid tumors.American journal of cancer research · 2026Article
- MR Image Fusion-Based Parotid Gland Tumor Detection.Journal of imaging informatics in medicine · 2025Article
- Analysis of microarray and single-cell RNA-seq identifies gene co-expression, cell-cell communication, and tumor environment associated with metabolite interconversion enzyme in prostate cancer.Discover oncology · 2025Article
- Clinical value of intratumoral and peritumoral CT radiomics models for discriminating benign and malignant parotid gland tumors.Frontiers in oncology · 2025Article
- Distinguishing atypical parotid carcinomas and pleomorphic adenomas based on multiphasic computed tomography radiomics nomogram: a multicenter study.Frontiers in oncology · 2025Article
- Applying deep learning-based ensemble model to [Japanese journal of radiology · 2025Article
- The value of T1- and FST2-Weighted-based radiomics nomogram in differentiating pleomorphic adenoma and Warthin tumor.Translational oncology · 2024Article
- Current Developments in Diagnosis of Salivary Gland Tumors: From Structure to Artificial Intelligence.Life (Basel, Switzerland) · 2024Review
- Article
- Preoperative CT-based intra- and peri-tumoral radiomic models for differentiating benign and malignant tumors of the parotid gland: a two-center study.American journal of cancer research · 2024Article
- Performance of radiomics in the differential diagnosis of parotid tumors: a systematic review.Frontiers in oncology · 2024Review
- Enhanced CT-based texture analysis and radiomics score for differentiation of pleomorphic adenoma, basal cell adenoma, and Warthin tumor of the parotid gland.Dento maxillo facial radiology · 2023Article
- CT-based radiomics with various classifiers for histological differentiation of parotid gland tumors.Frontiers in oncology · 2023Article
- Current Applications of Deep Learning and Radiomics on CT and CBCT for Maxillofacial Diseases.Diagnostics (Basel, Switzerland) · 2022Review
- The Role of Radiomics in Salivary Gland Imaging: A Systematic Review and Radiomics Quality Assessment.Diagnostics (Basel, Switzerland) · 2022Review
- The Impact of Image Acquisition Parameters and ComBat Harmonization on the Predictive Performance of Radiomics: A Renal Cell Carcinoma Model.Applied sciences (Basel, Switzerland) · 2022Article
- Artificial Intelligence-based Radiomics in the Era of Immuno-oncology.The oncologist · 2022Review
- Apparent Diffusion Coefficient Map-Based Radiomics Features for Differential Diagnosis of Pleomorphic Adenomas and Warthin Tumors From Malignant Tumors.Frontiers in oncology · 2022Article
- Comparison of Different Machine Models Based on Multi-Phase Computed Tomography Radiomic Analysis to Differentiate Parotid Basal Cell Adenoma From Pleomorphic Adenoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to develop and validate an integrated prediction model based on clinicoradiological data and computed tomography (CT)-radiomics for differentiating between benign and malignant parotid gland (PG) tumors MATERIALS AND
methodsA cohort of 87 PG tumor patients from hospital #1 who were diagnosed between January 2017 and January 2020 were used for prediction model training. A total of 378 radiomic features were extracted from a single tumor region of interest (ROI) of each patient on each phase of CT images. Imaging features were extracted from plain CT and contrast-enhanced CT (CECT) images. After dimensionality reduction, a radiomics signature was constructed. A combination model was constructed by incorporating the rad-score and CT radiological features. An independent group of 38 patients from hospital #2 was used to validate the prediction models. The model performances were evaluated by receiver operating characteristic (ROC) curve analysis, and decision curve analysis (DCA) was used to evaluate the clinical effectiveness of the models. The radiomics signature model was constructed and the rad-score was calculated based on selected imaging features from plain CT and CECT images.
resultsAnalysis of variance and multivariable logistic regression analysis showed that location, lymph node metastases, and rad-score were independent predictors of tumor malignant status. The ROC curves showed that the accuracy of the support vector machine (SVM)-based prediction model, radiomics signature, location and lymph node status in the training set was 0.854, 0.772, 0.679, and 0.632, respectively; specificity was 0.869, 0.878, 0.734, and 0.773; and sensitivity was 0.731, 0.808, 0.723, and 0.742. In the test set, the accuracy was 0.835, 0.771, 0.653, and 0.608, respectively; the specificity was 0.741, 0.889, 0.852, and 0.812; and the sensitivity was 0.818, 0.790, 0.731, and 0.716.
conclusionsThe combination model based on the radiomics signature and CT radiological features is capable of evaluating the malignancy of PG tumors and can help clinicians guide clinical tumor management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.